KEYTRUDA® (pembrolizumab) KEYNOTE-868 (NRG-GY018) clinical data presentation
Prescribing Information (United Kingdom) [External link]
Access the KEYNOTE-868 (NRG-GY018) clinical data presentation above to find out more about the trial design and study outcomes, including efficacy and safety.
Click on the resource to view.
KEYTRUDA, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.1
Refer to the Summary of Product Characteristics and Risk Minimisation Materials available on the emc website before prescribing, in order to help reduce the risk
associated with KEYTRUDA.
For more information about KEYTRUDA® (pembrolizumab) in advanced or recurrent endometrial cancer, click on the product page button below:
Reference
- KEYTRUDA Summary of Product Characteristics
Supporting documentation
Prescribing Information (United Kingdom) [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
